BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback